Jill Roberts Center for Inflammatory Bowel Disease
Found 123 results
Author Title Type [ Year(Asc)]
Filters: Filter is   [Clear All Filters]
2015
DeFilippis EM, Barfield E, Leifer D, Steinlauf A, Bosworth BP, Scherl EJ, Sockolow R.  2015.  Cerebral venous thrombosis in inflammatory bowel disease.. J Dig Dis. 16(2):104-8.
Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al..  2015.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.
Chen HJoyce, Sun J, Huang Z, Hou H, Arcilla M, Rakhilin N, Joe DJ, Choi J, Gadamsetty P, Milsom J et al..  2015.  Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.. Nat Biotechnol. 33(6):656-60.
Gerbarg PL, Jacob VE, Stevens L, Bosworth BP, Chabouni F, DeFilippis EM, Warren R, Trivellas M, Patel PV, Webb CD et al..  2015.  The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial.. Inflamm Bowel Dis. 21(12):2886-96.
Longman RS, Littman DR.  2015.  The functional impact of the intestinal microbiome on mucosal immunity and systemic autoimmunity.. Curr Opin Rheumatol. 27(4):381-7.
Kiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H.  2015.  Treatment of metastatic cutaneous Crohn disease with certolizumab.. Dermatol Online J. 21(11)
Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD.  2015.  Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.
Hirten R, Longman RS, Bosworth BP, Steinlauf A, Scherl E.  2015.  Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.. Am J Gastroenterol. 110(12):1737-8.
2014
Longman RS, Diehl GE, Victorio DA, Huh JR, Galan C, Miraldi ER, Swaminath A, Bonneau R, Scherl EJ, Littman DR.  2014.  CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.. J Exp Med. 211(8):1571-83.
Zhang N, Yantiss RK, Nam H-S, Chin Y, Zhou XKathy, Scherl EJ, Bosworth BP, Subbaramaiah K, Dannenberg AJ, Benezra R.  2014.  ID1 is a functional marker for intestinal stem and progenitor cells required for normal response to injury.. Stem Cell Reports. 3(5):716-24.
Dogan B, Suzuki H, Herlekar D, R Sartor B, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP et al..  2014.  Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.. Inflamm Bowel Dis. 20(11):1919-32.
Battat R, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, Bessissow T, Seidman E, Bitton A.  2014.  Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management.. Inflamm Bowel Dis. 20(6):1120-8.
2013
Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB et al..  2013.  Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis.. Elife (Cambridge). 2:e01202.
Diehl GE, Longman RS, Zhang J-X, Breart B, Galan C, Cuesta A, Schwab SR, Littman DR.  2013.  Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells.. Nature. 494(7435):116-20.
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..  2013.  Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Kothary V, Scherl EJ, Bosworth B, Jiang Z-D, Dupont HL, Harel J, Simpson KW, Dogan B.  2013.  Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. Antimicrob Agents Chemother. 57(2):811-7.
Montrose DC, Scherl EJ, Bosworth BP, Zhou XKathy, Jung B, Dannenberg AJ, Hla T.  2013.  S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.. J Lipid Res. 54(3):843-51.
2012
Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, Bowman D, Scherl EJ, Simpson KW.  2012.  Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease.. PLoS One. 7(7):e41594.
Shen T-CDavid, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D et al..  2012.  Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.. J Clin Neuromuscul Dis. 13(3):137-45.
Longman RS, Moreira RK, Littman DR, Green PHR, Sethi A.  2012.  A rare intestinal infection with systemic effects.. Gastroenterol Hepatol (N Y). 8(1):60-3.
Koczka CPhilip, Abramowitz M, Goodman AJ.  2012.  The study of bone demineralization and its risk factors in an Afro-Caribbean subset of patients with inflammatory bowel disease.. Eur J Gastroenterol Hepatol. 24(7):759-61.
2011
Verma HDev, Scherl EJanice, Jacob VElizabeth, Bosworth BPaul.  2011.  Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.. J Dig Dis. 12(5):379-83.
Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, Mechanick JI, Zaidi M.  2011.  Bone, inflammation, and inflammatory bowel disease.. Curr Osteoporos Rep. 9(4):251-7.
Longman RS, Remotti H, Green PH.  2011.  Esophagitis dissecans superficialis.. Gastrointest Endosc. 74(2):403-4.
Steinlauf AF, Marion JF, Sacchar D, Sandler AL, Greenstein AJ, Harris MT.  2011.  Ileouterine fistulae: possible predisposing factors to this rare complication of Crohn's disease.. Inflamm Bowel Dis. 17(3):872-3.